ESH MM 2018 | Real world data for len/dex in second-line myeloma: what does this tell us?
Real world data can shed new light upon the results of similar treatments in trials, as the study discussed here by Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, did. Dr Terpos discusses what the real world data for lenalidomide plus dexamethasone in the second-line setting for multiple myeloma (MM) has revealed. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
Get great new content delivered to your inboxSign up